2:01 PM · 20 December 2024

BREAKING: Novo Nordisk shares lose 20% amid weak performance by CagriSema🚨

Novo Nordisk
Stocks
NOVOB.DK, Novo Nordisk A/S
-
-

Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

 

The company's shares are trading at their lowest since August 2023. Source: xStation 

14 October 2025, 11:16 AM

Ericsson surprises with results. Shares rise following new Vodafone deal

14 October 2025, 10:12 AM

Michelin cuts its 2025 forecasts, shares plunge!

14 October 2025, 9:23 AM

EasyJet volatility spikes after takeover rumors 💡

13 October 2025, 5:05 PM

Goldman Sachs boosts sentiment on Estée Lauder shares 💡

Join over 1 700 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits